On June 28, the U.S. Food and Drug Administration (FDA) approved Brisdelle (paroxetine) to treat moderate to severe hot flashes associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only nonhormonal treatment for hot flashes approved by the FDA. Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder